Side-by-side comparison of AI visibility scores, market position, and capabilities
British consumer health company with £14B revenue; Lysol, Mucinex, Nurofen, and Durex brands managing Mead Johnson infant formula litigation while competing with P&G and J&J.
Reckitt is a British multinational consumer health and hygiene company producing market-leading brands including Nurofen (ibuprofen), Strepsils, Dettol, Lysol, Durex, Mucinex, Enfamil infant formula, and Woolite — competing across OTC health, hygiene and home, and nutrition categories. Listed on the London Stock Exchange (LSE: RKT) and headquartered in Slough, England, Reckitt generates approximately £14 billion ($17 billion) in annual revenue. The company has undergone significant portfolio reshaping, divesting its Infant Formula & Child Nutrition (IFCN) business in some markets and selling Mead Johnson Nutrition operations.\n\nReckitt's business is organized into two segments: Health (Nurofen, Strepsils, Gaviscon, Mucinex, DayQuil/NyQuil in North America) and Hygiene and Home (Lysol/Dettol disinfectants, Finish dishwasher tablets, Vanish stain remover, Air Wick). The Health segment benefits from strong brand equity in OTC medications that command premium pricing. The Hygiene segment's Lysol brand benefited significantly from COVID-19 disinfectant demand and has sustained elevated brand awareness post-pandemic.\n\nIn 2025, Reckitt faces ongoing challenges from its $2.4 billion acquisition of Mead Johnson (Enfamil) — the company has faced significant litigation related to NEC (necrotizing enterocolitis) lawsuits claiming preterm infant formula contributed to infant deaths, resulting in large court judgments against Reckitt in 2024. The company is managing these legal liabilities while continuing to run its core consumer health and hygiene portfolio. Reckitt competes with Procter & Gamble, Johnson & Johnson, and Haleon for OTC health and hygiene market share. The 2025 strategy focuses on its Power Brands in health and hygiene, cost efficiency, and resolving the Mead Johnson litigation exposure.
$2.3B raised at $29.3B valuation; $2B+ ARR (Q1 2026); used by 50%+ of Fortune 500. Dominant commercial AI coding tool; built on VSCode fork with native agent mode. Competing with GitHub Copilot, Windsurf, and Lovable in the vibe-coding wave.
Cursor is an AI-powered code editor built on Visual Studio Code that integrates advanced language models to provide intelligent code completion, generation, debugging, and refactoring capabilities directly in the development workflow. The company serves software developers seeking to accelerate coding productivity through AI assistance while maintaining full control and understanding of their code. Cursor delivers value through contextual code suggestions that understand entire codebases, natural language commands to modify code, inline AI chat for explaining complex code, and a familiar VS Code interface that requires minimal learning curve for existing developers.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.